Europe’s Next Translation: Mapping the Networks Behind Cell and Gene Therapy
As the industry gathers in Seville for ESGCT 2025, the conversation is turning toward scale, connectivity, and what comes next for Europe’s cell and gene therapy field (CGT). At Lonrú Consulting, we wanted to look across the ecosystem to understand where strength already exists, where new capability is forming, and where opportunity lies.
To do that, we built the Translational Network Atlas.
The Atlas is a data-driven visualisation of Europe’s CGT landscape. It brings together comparable metrics on translational infrastructure, manufacturing capability, scientific output, and cross-border collaboration for sixteen European countries. Each country is represented by a Composite CGT Readiness Score, built from Lonrú’s underlying Collaboration and Infrastructure Dataset.
The goal is simple: to see the European CGT ecosystem as it really functions, not as disparate national efforts but as a connected system of translational engines.
About the Methodology
Each country’s Composite Score represents the weighted average of five underlying factors that describe its cell and gene therapy (CGT) ecosystem:
European Network Integration – how connected the country is to major European translational frameworks and consortia
Translational Platform Maturity – how well-developed its clinical and regulatory infrastructure is
ATMP Manufacturing and Execution Capacity – the scale and readiness of its GMP and technology transfer capabilities
Cross-Border Collaboration Participation – how active it is in regional or multi-country initiatives
CGT Publication Intensity – how much peer-reviewed research output the country contributes to the field
Each metric is scored from 0 to 5 and weighted by importance. Under the Balanced preset:
Integration: 25%
Maturity: 25%
Manufacturing: 20%
Collaboration: 15%
Publications: 15%
The Calculation
For a country c, with metric values I, M, F, C, and P (each between 0 and 5) and weights wI, wM, wF, wC, and wP (expressed as percentages), the Composite Score is calculated as:
This is a weighted average of the five metrics on a 0–5 scale.
Example (illustrative only)
If a country has Integration = 5, Maturity = 4, Manufacturing = 5, Collaboration = 2.5, Publications = 3.5, then under the Balanced weighting:
= 4.15
Note: These values are for demonstration only and do not represent live scores.
Why It Matters
The weighting tells the index what to prioritise. Policy-focused users might emphasise Integration and Maturity; industry users might give more weight to Manufacturing; academic users might focus on Collaboration and Publications. The same formula applies no matter the weighting - it simply reflects a different perspective on the same ecosystem data.
What the Atlas Reveals
The early findings show a continent defined by complementarity rather than competition.
The UK, France, and Germany form Europe’s industrial and translational core, linking advanced manufacturing with regulatory sophistication.
The Netherlands, Spain, and Italy bridge academia and execution, combining strong research output with GMP expansion.
The Nordic cluster stands out for its network-driven collaboration model, while Ireland, Portugal, and Austria are investing strategically to accelerate translational maturity.
Across all regions, integration is deepening. Europe’s collective CGT capacity is becoming more networked, more balanced, and more visible.
Explore the Atlas
The Translational Network Atlas is available to explore below where users can move across the global map, compare national CGT readiness profiles, and see how integration, maturity, and knowledge interact to shape the future of advanced therapy translation. This tool is not a ranking but is instead a window into how Europe’s CGT engine operates and where the next translational opportunities may appear.
For custom research and data visualisation tools contact Lonrú Consulting.
